These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 16623874)

  • 1. Cyclosporine A versus tacrolimus monotherapy. Comparison on bile lipids in the first 3 months after liver transplant in humans.
    Baiocchi L; Angelico M; De Luca L; Ombres D; Anselmo A; Telesca C; Orlando G; D'Andria D; Tisone G
    Transpl Int; 2006 May; 19(5):389-95. PubMed ID: 16623874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy.
    Charco R; Cantarell C; Vargas V; Capdevila L; Lázaro JL; Hidalgo E; Murio E; Margarit C
    Liver Transpl Surg; 1999 May; 5(3):204-8. PubMed ID: 10226111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of changing immunosuppressive monotherapy from Cyclosporin A to Tacrolimus in long-term, stable liver transplant recipients.
    Ott R; Bussenius-Kammerer M; Reck T; Koch CA; Kissler H; Hohenberger W; Müller V
    Transpl Int; 2004 Jan; 17(1):39-43. PubMed ID: 14504723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
    Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R
    Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired erythropoietin production in liver transplant recipients: the role of calcineurin inhibitors.
    Bardet V; Junior AP; Coste J; Lecoq-Lafon C; Chouzenoux S; Bernard D; Soubrane O; Lacombe C; Calmus Y; Conti F
    Liver Transpl; 2006 Nov; 12(11):1649-54. PubMed ID: 17058250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure profile and treatment quality in liver allograft recipients-benefit of tacrolimus versus cyclosporine.
    Dikow R; Degenhard M; Kraus T; Sauer P; Schemmer P; Uhl W; Büchler M; Zeier M
    Transplant Proc; 2004 Jun; 36(5):1512-5. PubMed ID: 15251373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine.
    Villamil F; Levy G; Grazi GL; Mies S; Samuel D; Sanjuan F; Rossi M; Lake J; Munn S; Mühlbacher F; Leonardi L; Cillo U
    Transplant Proc; 2006 Nov; 38(9):2964-7. PubMed ID: 17112875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
    Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
    J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact on biochemical profiles and allograft function for patients converted from cyclosporine to tacrolimus after clinical heart transplantation.
    Wang CH; Chou NK; Ko WJ; Chi NH; Tsao CI; Wang SS
    Transplant Proc; 2008 Oct; 40(8):2600-2. PubMed ID: 18929812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporine A-induced reduction of bile salt synthesis associated with increased plasma lipids in children after liver transplantation.
    Hulzebos CV; Bijleveld CM; Stellaard F; Kuipers F; Fidler V; Slooff MJ; Peeters PM; Sauer PJ; Verkade HJ
    Liver Transpl; 2004 Jul; 10(7):872-80. PubMed ID: 15237371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
    Vivarelli M; Cucchetti A; La Barba G; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
    Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subclinical inflammation in renal transplant recipients: impact of cyclosporine microemulsion versus tacrolimus.
    Lauzurica R; Pastor MC; Bayes B; Malumbres S; Homs M; Llopis MA; Bonet J; Romero R
    Transplant Proc; 2007 Sep; 39(7):2170-2. PubMed ID: 17889127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tacrolimus monotherapy in liver transplantation: one-year results of a prospective, randomized, double-blind, placebo-controlled study.
    Lerut J; Mathys J; Verbaandert C; Talpe S; Ciccarelli O; Lemaire J; Bonaccorsi-Riani E; Vanthuyne V; Hetsch N; Roggen F; Reyck CD; Goffette P; Latinne D; Orlando G; Rahier J; Sempoux C; Wallemacq P; Laterre PF; Gianello P
    Ann Surg; 2008 Dec; 248(6):956-67. PubMed ID: 19092340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of oral fructose load on serum uric acid and lipids in kidney transplant recipients treated with cyclosporine or tacrolimus.
    Zawiasa A; Szklarek-Kubicka M; Fijałkowska-Morawska J; Nowak D; Rysz J; Mamełka B; Nowicki M
    Transplant Proc; 2009; 41(1):188-91. PubMed ID: 19249511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients.
    Sánchez-Pérez B; Aranda Narváez JM; Santoyo Santoyo J; Fernández-Aguilar JL; Suárez Muñoz MA; González-Sánchez AJ; Pérez Daga JA; Ramírez Plaza CP; Carrasco Campos J; Jiménez Mazure C; Becerra Ortíz R
    Transplant Proc; 2008 Nov; 40(9):2994-6. PubMed ID: 19010171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac function after orthotopic liver transplantation and the effects of immunosuppression: a prospective randomized trial comparing cyclosporin (Neoral) and tacrolimus.
    Therapondos G; Flapan AD; Dollinger MM; Garden OJ; Plevris JN; Hayes PC
    Liver Transpl; 2002 Aug; 8(8):690-700. PubMed ID: 12149762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus as intervention in the treatment of hyperlipidemia after liver transplant.
    Roy A; Kneteman N; Lilly L; Marotta P; Peltekian K; Scudamore C; Tchervenkov J
    Transplantation; 2006 Aug; 82(4):494-500. PubMed ID: 16926593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.